Skip to main content
Fig. 5 | Cancer & Metabolism

Fig. 5

From: CD36 inhibition enhances the anti-proliferative effects of PI3K inhibitors in PTEN-loss anti-HER2 resistant breast cancer cells

Fig. 5

The combination strategy to suppress tumor cell proliferation in anti-HER2 resistant PTEN-deficient breast cancer cells. The constitutive activation of the HER2/PI3K/AKT/mTOR pathway led to the remodeling of lipid metabolism and cell proliferation in HER2-positive breast cancer cells with PIK3CA mutation or PTEN loss. SCD-1 and CD36 are highly expressed in anti-HER2 resistant breast cancer cells with PTEN loss. Simultaneously blocking the PI3K/AKT/mTOR signaling pathway and inhibiting CD36 significantly reduces the proliferation of anti-HER2 resistant breast cancer cells with PTEN-loss

Back to article page

Cancer & Metabolism

ISSN: 2049-3002